Onvansertib effectively targets the once “undruggable” KRAS-mutation present in 50% of colorectal cancer
New Podcast
Skip to content
FOR INVESTORS
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Onvansertib
Pipeline
Clinical Programs
mCRC
mCRPC
mPDAC
Leadership
Management Team
Board of Directors
Scientific Advisory Board
Contact Us
For Investors
News and Events
Corporate Presentation
Stock Information
Shareholder Services
SEC Filings
Corporate Governance
Investor Relations
Board of Directors
Board Committees
Committee Charters
Code of Conduct
Ethics and Compliance Hotline
Board Committees
Executive Compensation Committee
Description of Executive Compensation Committee
Rodney S. Markin, M.D.
Gary W. Pace, Ph.D.
Renee Tannenbaum
